Aging‐Dependent Hepatic YAP1 Reduction Promotes Metabolic Dysfunction‐Associated Steatotic Liver Disease via Gut Microbiota Dysbiosis With Akkermansia muciniphila Downregulation
The FASEB Journal · 31.03.2026 · 40 (6)
DOI: 10.1096/fj.202504071r ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, online erschienen am 19.03.2026. Verfasst von Yuting Gao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Integrated Medicine Tumor Immunology, Shanxi University of Chinese Medicine, Taiyuan, China. Hauptthemen laut MEDLINE: Aging, Gastrointestinal Microbiome, Liver, Fatty Liver. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 51 Literaturangaben.
Abstract (Originalsprache)
Aging is associated with progressive liver dysfunction and increased risk of metabolic dysfunction‐associated steatotic liver disease (MASLD), although the underlying molecular mechanisms remain incompletely understood. In this study, we explored the role of Yes‐associated protein 1 (YAP1) in liver aging by using adeno‐associated virus serotype 8 (AAV8) based approaches to create hepatocyte‐specific Yap1 knockout mice. We found that hepatic YAP1 expression declined with age, and loss of hepatocyte YAP1 accelerated liver aging, characterized by increased senescence, impaired proliferative capacity, and DNA damage. YAP1 deficiency was associated with activation of the cGAS–STING pathway, increased oxidative stress and triglyceride accumulation, and the development of MASLD. Additionally, the loss of YAP1 disrupted the composition of the gut microbiota, decreased the abundance of Akkermansia muciniphila ( A. muciniphila ), and impaired intestinal barrier function. Notably, microbiota depletion abolished Yap1 deletion‐induced senescence and MASLD, while A. muciniphila supplementation improved gut barrier integrity and alleviated MASLD‐associated phenotypes. Together, these findings indicate that aging‐dependent hepatic YAP1 reduction promotes MASLD through mechanisms involving DNA damage, oxidative stress, and gut microbiota dysbiosis, with reduced A. muciniphila abundance representing a prominent associated feature. This highlights the YAP1‐gut microbiota axis as a potential therapeutic target for liver diseases associated with aging.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Integrated Medicine Tumor Immunology, Shanxi University of Chinese Medicine, Taiyuan, China.
ORCID-Profile: Xinli Shi
Zitieren
APA
Gao, Y., Lu, J., Du, Z., Gong, Y., Song, X., Xiong, Y., Yang, Y., & Shi, X. (2026). Aging‐Dependent Hepatic YAP1 Reduction Promotes Metabolic Dysfunction‐Associated Steatotic Liver Disease via Gut Microbiota Dysbiosis With Akkermansia muciniphila Downregulation. The FASEB Journal, 40(6). https://doi.org/10.1096/fj.202504071r
Vancouver
Gao Y, Lu J, Du Z, Gong Y, Song X, Xiong Y, et al. Aging‐Dependent Hepatic YAP1 Reduction Promotes Metabolic Dysfunction‐Associated Steatotic Liver Disease via Gut Microbiota Dysbiosis With Akkermansia muciniphila Downregulation. The FASEB Journal. 2026;40(6). doi:10.1096/fj.202504071r
BibTeX
@article{Gao2026,
author = {Gao, Yuting and Lu, Junlan and Du, Zhimin and Gong, Yi and Song, Xiaoyong and Xiong, Yajun and Yang, Yanguang and Shi, Xinli},
title = {Aging‐Dependent Hepatic YAP1 Reduction Promotes Metabolic Dysfunction‐Associated Steatotic Liver Disease via Gut Microbiota Dysbiosis With Akkermansia muciniphila Downregulation},
journal = {The FASEB Journal},
year = {2026},
volume = {40},
number = {6},
doi = {10.1096/fj.202504071r}
}
EUVIMED